X0306 4 2012-11-29 0 0001176309 ORAMED PHARMACEUTICALS INC. ORMP 0001542838 REGALS CAPITAL MANAGEMENT LP 152 WEST 57TH STREET 9TH FLOOR NEW YORK NY 10019 0 0 1 0 0001542836 Regals Fund LP 152 WEST 57TH STREET, 9TH FLOOR NEW YORK NY 10019 0 0 1 0 0001477733 Slager David Mark 152 WEST 57TH STREET, 9TH FLOOR NEW YORK NY 10019 0 0 1 0 Warrants (Right to Purchase) .6 2012-11-29 4 P 0 1647722 A 2012-11-29 2016-11-29 Common Stock 1647722 1647722 I See Warrants (Right to Purchase) .5 2012-11-30 4 H 0 202703 D 2012-11-05 2017-11-05 Common Stock 202703 0 I See Warrants (Right to Purchase) .3138 2012-11-30 4 P 0 202703 A 2012-11-30 2017-11-05 Common Stock 202703 202703 I See Warrants (Right to Purchase) .5 2012-11-29 4 H 0 1351352 D 2012-08-28 2017-08-28 Common Stock 1351352 0 I See Warrants (Right to Purchase) .3138 2012-11-29 4 P 0 1351352 A 2012-11-29 2017-08-28 Common Stock 1351352 1351352 I See Warrants (Right to Purchase) .3138 2012-11-29 4 H 0 3485500 D 2012-01-10 2016-01-10 Common Stock 3485500 0 I See Warrants (Right to Purchase) .3138 2012-11-29 4 P 0 3485500 A 2012-11-29 2016-01-10 Common Stock 3485500 3485500 I See On November 29, 2012, the Regals Fund LP, a Delaware limited partnership (the "Fund"), and the issuer amended the terms of the warrants previously issued by the issuer to the Fund by: (a) changing the exercise price of such warrants to $.3118, and/or (b) deleting any anti-dilution provisions with respect to new issuances from such warrants. In exchange for agreeing to amend the warrants, the Fund received an additional warrant exercisable for 1,647,722 shares of common stock and an option from an affiliate of the issuer to purchase up to 1,352,278 shares of common stock at a variable exercise price upon a trigger event. The exercise price for such warrants reflects the exercise price after taking into account anti-dilution adjustments that occurred pursuant to the terms of such warrants (prior to the amendments described in note #1 above). The number of shares underlying such warrants reflect the number of shares the warrants are exercisable for after taking into account anti-dilution adjustments that occurred pursuant to the terms of such warrants (prior to the amendments described in note #1 above). Regals Capital Management LP, a Delaware limited partnership ("Regals Management"), the Fund, and David M. Slager ("Mr. Slager"), are the reporting persons (the "Reporting Persons") for the referenced securities. Mr. Slager is Managing Member of the general partner of Regals Management. Regals Management is the investment manager of the Fund. The shares of the issuer's common stock reported herein are held for the account of the Fund. As a result, each of the Reporting Persons may be deemed to be a beneficial owner of the securities owned by the Fund for purposes of Rule 16a-1(a)(1) under the Securities Exchange Act of 1934, as amended (the "Act"). Pursuant to Rule 16a-1(a)(4) under the Act, Regals Management and Mr. Slager disclaim beneficial ownership in the securities owned by the Fund except to the extent, if any, of their pecuniary interest therein. David M. Slager, as Managing Member of Regals Capital Holdings LLC, general partner of Regals Capital Management LP 2012-12-13 David M. Slager, as Managing Member of Regals Fund GP LLC, general partner of Regals Fund, LP 2012-12-13 David M. Slager 2012-12-13